First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018

IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy (ABRAXANE plus atezolizumab) combination in first-line metastatic triple negative breast cancer (TNBC) patients. IMpower130 demonstrated significant overall survival (OS) and progression-free survival (PFS) benefit of ABRAXANE/carboplatin plus atezolizumab in advanced non-squamous non-small cell lung cancer (NSCLC) patients.